Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

196.54 -4.99 (-2.48%)
Streaming Delayed Price Updated: 11:40 AM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,240,393
Open 199.40
Bid (Size) 196.51 (100)
Ask (Size) 196.79 (100)
Prev. Close 201.53
Today's Range 196.50 - 199.52
52wk Range 183.63 - 212.71
Shares Outstanding N/A
Dividend Yield 0.47%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗
Compugen (CGEN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗
Via MarketBeat
Topics ETFs

Performance

YTD
+4.3%
+4.3%
1 Month
+4.3%
+4.3%
3 Month
+4.3%
+4.3%
6 Month
+4.3%
+4.3%
1 Year
+4.3%
+4.3%

More News

Read More
News headline image
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
Via MarketMinute
Topics Economy Intellectual Property
News headline image
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange
Via MarketMinute
Topics ETFs
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
Via MarketMinute
Topics Intellectual Property
News headline image
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
From AstraZeneca
Via Business Wire
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
Via MarketMinute
Topics Intellectual Property
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
From AstraZeneca
Via Business Wire
News headline image
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH ↗
Via MarketBeat
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
Via Finterra
Topics Economy Intellectual Property
News headline image
The Great Rebound: 2026 Becomes the Year of the Strategic Mega-Deal as M&A Activity Surges
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Via Finterra
Topics Economy Intellectual Property
News headline image
The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026
Via Finterra
Topics Artificial Intelligence Economy Fraud
News headline image
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Via FinancialNewsMedia
News headline image
AstraZeneca results: FY and Q4 2025
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance
Via Finterra
Topics Economy Government Intellectual Property
News headline image
Trade War 2.0: 25% Tariffs on Chips, Cars, and Medicine Reshape the Global Supply Chain
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
OAK Family Advisors Sells $4 Million of NICE Stock ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
From AstraZeneca
Via Business Wire

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 196.54
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 03/05/26 11:40 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.